Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis

Upadacitinib plus topical corticosteroids in atopic dermatitis: week-52 AD Up study results

(2021) Jonathan I. Silverberg et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials

(2021) Emma Guttman-Yassky et al.   LANCET

Efficacy and Safety of Upadacitinib vs Dupilumab in Adults With Moderate-to-Severe Atopic Dermatitis

(2021) Andrew Blauvelt et al.   JAMA Dermatology

The validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD™): The development and reliability testing of a novel clinical outcome measurement instrument for the severity of atopic dermatitis

(2020) Eric Simpson et al.   JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY

P209 Safety profile of upadacitinib in rheumatoid arthritis: integrated analysis from the select Phase 3 clinical programme

(2020) Stanley B Cohen et al.   RHEUMATOLOGY

Atopic dermatitis

(2020) Sinéad M Langan et al.   LANCET

Upadacitinib in Adults With Moderate-to-Severe Atopic Dermatitis: 16-Week Results From a Randomized, Placebo-Controlled Trial

(2019) Emma Guttman-Yassky et al.   JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY

Atopic dermatitis epidemiology and unmet need in the United Kingdom

(2019) Michael J. Cork et al.   JOURNAL OF DERMATOLOGICAL TREATMENT

Atopic dermatitis

(2018) Stephan Weidinger et al.   Nature Reviews Disease Primers

JAK Inhibitors for Atopic Dermatitis: An Update

(2018) Helen He et al.   AMERICAN JOURNAL OF CLINICAL DERMATOLOGY

Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis

(2016) Eric L. Simpson et al.   NEW ENGLAND JOURNAL OF MEDICINE